Defective systemic and local iron metabolism correlates with cardiac disorders. Hepcidin, a master iron sensor, actively tunes iron trafficking. We hypothesized that hepcidin could play a key role to locally regulate cardiac homeostasis after acute myocardial infarction.
RESULTS:
We found that the expression of hepcidin was elevated after acute myocardial infarction and the specific deletion of hepcidin in cardiomyocytes failed to improve cardiac repair and function. However, transplantation of bone marrow-derived cells from hepcidin-deficient mice (Hamp /chemokine (C-C motif) receptor 2 (CCR2) + inflammatory macrophages and fostered signal transducer and activator of transcription factor-3 (STAT3) phosphorylation, an instrumental step in the release of IL-4 and IL-13. The combined genetic suppression of hepcidin and IL-4/ IL-13 in macrophages failed to improve cardiac function in both adult and neonatal injured hearts.
ffective iron homeostasis is essential to cardiovascular health. Iron deficiency is frequent in patients with coronary artery diseases and increases morbidity in individuals with high-risk profiles, especially for people with diabetes mellitus. 1 Likewise, in patients with heart failure, anemia is common and an independent prognostic factor for mortality, prompting the development of iron therapy in affected individuals. 1 Conversely, excess iron is also detrimental to cardiac function. As such, iron-overload cardiomyopathy is the most common cause of mortality in patients with secondary iron overload and is a major comorbidity in patients with genetic hemochromatosis. 1 Among the multiple regulators of iron homeostasis, hepcidin plays an instrumental role in fine-tuning systemic iron trafficking by modulating the transfer of dietary, recycled, and stored iron from intracellular compartments to extracellular fluids. 2 Hepcidin is a cationic peptide hormone produced primarily by hepatocytes but also by other professional iron regulatory cells such as macrophages. Hepcidin binds to the cell surface iron exporter, ferroportin, inducing its internalization and degradation, thus dampening iron efflux. 3 Consistent with this, hepcidin-deficient mice or humans with ferroportin variants resistant to hepcidin-induced degradation become iron overloaded. 4, 5 Conversely, severe iron deficiency anaemia is observed in mice or humans overexpressing hepcidin. 4, 6 Hepcidin synthesis is downregulated by iron deficiency, hypoxia, and erythropoietic drive, 7 whereas increase in iron, bone morphogenic protein signaling pathway, and endoplasmic reticulum stress enhance mRNA levels of Hamp, the gene encoding hepcidin. 8 Hepcidin is also localized in tissues including the brain, the kidney, the placenta, and the heart, 9, 10 with no essential role in systemic iron trafficking, suggesting that the extrahepatic pool of hepcidin is instrumental in locally regulating tissue iron homeostasis. Importantly, in the healthy adult heart, cardiomyocyte-specific deletion of hepcidin or ferroportin did not regulate systemic iron flux but rather directed cardiac iron content, leading to long-term heart dysfunction. 10, 11 In experimental models of proinflammatory autoimmune myocarditis, the expression of hepcidin was elevated. 9 Hamp mRNA levels were increased in response to interleukin (IL)-6, and toll-like receptor 4-binding pathogens in cultured macrophages. 12, 13 Remarkably, only Hamp transcript levels were transiently upregulated in the ischemic myocardium, whereas those of other iron-related genes, such as hemojuvelin and iron-regulated transporter 1, were unaffected.
14 Given the role of hepcidin to locally regulate cardiac function, and that inflammation guides cardiac remodeling after acute myocardial infarction (AMI), we hypothesized that inflammatory macrophages may control cardiac repair through a hepcidin-dependent mechanism. Until now, the role of hepcidin in cardiac diseases challenged by inflammation remained unexplored. Using newly developed murine models of hepcidin deficiency, we showed that hepcidin impedes IL-4 and IL-13 release by inflammatory cardiac macrophages and subsequently limits cardiac healing and regeneration after heart injury.
METHODS
The data, analytic methods, and study are available from the corresponding author on reasonable request.
Experimental Procedures
All experiments were conducted according to the ethical committee for animal experimentation (Paris Descartes University, CEEA 34) 
Clinical Perspective
What Is New?
• The hormone hepcidin is produced by a distinct subpopulation of inflammatory cardiac macrophages residing in the infarcted heart. • The deletion of hepcidin in macrophages improves tissue remodeling and stimulates cardiomyocyte renewal in both adult mice with myocardial infarction and neonatal animals with apical resection.
• Interleukin (IL)-6 enhances mRNA expression of Hamp, the gene encoding hepcidin, and the upregulation of hepcidin abrogates the secretion of IL-4 and IL-13 through signal transducer and activator of transcription factor 3 by inflammatory macrophages.
• The combined genetic suppression of hepcidin and IL-4/IL-13 in macrophages fails to improve cardiac repair in both adult and neonatal injured hearts.
What Are the Clinical Implications?
• Our study provides novel insights into the complex roles of the immune response during cardiac repair after myocardial infarction and suggests a deleterious role for macrophage-derived hepcidin in cardiac repair.
• Hepcidin is an upstream repressor of reparatory cytokines (IL-4 and IL-13) secreted by cardiac macrophages. Investigating macrophage paracrine potential could provide valuable insights for therapeutic interventions.
• This study supports the concept that acute therapeutic modulation of innate immunity might prevent postinfarction heart failure.
• Our work could stimulate further research deciphering the effective contribution of bona fide cardiomyocyte regeneration in tissue repair within the adult injured heart. /Hamp f/f mice, and their respective controls were on a C57BL/6J background. All experiments were performed with 10-to 25-week-old male animals and were carried out using ageand littermate-matched groups without randomization. In the neonatal cardiac injury model, all experiments were performed with day 1 postnatal mice without knowledge of genotype. Immunohistochemistry and echocardiography analysis were performed without knowledge of genotype or treatment. Sample size has not been predetermined by statistical method. Adult mice dying within 24 hours of coronary artery ligation surgery (<10% in all genotypes studied) were prespecified as purely technical failures and excluded from subsequent analysis.
ORIGINAL RESEARCH ARTICLE

Myocardial Infarction
Myocardial infarction was induced by left coronary ligation as previously described. 16 Mice were anesthetized using ketamine (100 mg/kg body weight) and xylazine (10 mg/kg body weight) via intraperitoneal injection, intubated, and ventilated using a small-animal respirator. The chest wall was shaved and a thoracotomy was performed in the fourth left intercostal space. The pericardial sac was removed, and the left anterior descending artery was permanently ligated at the site of its emergence close to the left atrium. The thoracotomy was closed with 6-0 monofilament sutures. The exact same procedure was performed for the sham-operated mice except that the ligation was not tied. The endotracheal tube was removed once spontaneous respiration resumed, and mice were placed on a warm pad at 37°C until awakened.
Neonatal Model of Cardiac Regeneration
Apical resection surgeries were performed on neonatal mice at postnatal day 1. Neonates were anesthetized by cooling on an ice bed. Lateral thoracotomy was performed at the fourth intercostal space. The heart was visualized and exteriorized outside the chest cavity. The ventricular apex was resected with iridectomy scissors, and 15% to 20% of the left ventricle was resected. Neonates were removed from the ice bed, and thoracic wall incisions were sutured with 6-0 nonabsorbable silk suture. Neonates were then placed under a heat lamp and warmed for several minutes until recovery as previously described.
17
Bone Marrow-Derived Cell Transplantation
Bone marrow (BM) cells were obtained by flushing tibiae and femora of donor mice. Wild-type (WT) C57BL/6J mice were lethally irradiated with a total dose of 9.5 Gy and were intravenously injected 24 
Cardiac Digestion and Flow Cytometry
Hearts were collected and the left ventricle was isolated, minced with fine scissors, and gently passed through the BelArt Scienceware 12-Well Tissue Disaggregator (Fisher Scientific). Cells were collected, filtered through 40-μm nylon mesh, and washed with PBS with 1% vol/vol fetal bovine serum. Red blood cells were removed by incubation in hemolysis buffer (StemCell Technologies). Cells were counted and used for fluorescenceactivated cell sorting or analyzer, as previously described. 19 Cells harvested from the heart were stained in PBS at 4°C. Total cardiac cells were gated on Alexa Fluor 700-conjugated CD45 (30-F11, BD Biosciences), and the following antibodies were used: Pe-Cy7-conjugated anti-CD11b (M1/70, BD Pharmingen), phycoerythrin-conjugated anti-Ly6G (1A8, BD Pharmingen), BV421-conjugated anti-CD64 (X54-5/7.1, Biolegend), allophycocyanin-conjugated anti-F4/80 (MCA497, AbD Serotec, Bio-Rad), fluorescein isothiocyanate-conjugated anti-Ly6C (AL-21, BD Pharmingen), Percp5.5-conjugated MHCII (M5/114.15.2, BD Pharmingen), phycoerythrin-conjugated anti-CCR2 (R&D Systems Europe), PerCP-conjugated anti-CD8a (53-6.7, BD Pharmingen), phycoerythrin-conjugated anti-CD45R/B220 (RA3-6B2, eBioscience), phycoerythrin-Cy7-conjugated anti-CD3 (145-2C11, BD Pharmingen), and fluorescein isothiocyanate-conjugated anti-CD4 (RM4-5, BD Pharmingen). All antibodies were used at a dilution of 1:100. The total number of cells was then normalized to heart weight. Events were acquired on an LSR II flow cytometer (BD Biosciences) or were sorted with FACSAria II (BD Biosciences), and results were analyzed on FlowJo software.
Statistical Analysis
Kruskal-Wallis 1-way ANOVA was used to compare each measure when there were ≥3 independent groups. Comparisons between groups were then performed using the Dunn multiple comparisons test when the ANOVA test was statistically significant. The Mann-Whitney test was used to compare 2 groups. Statistical significance of Kaplan-Meier survival curves was assessed with a Mantel-Cox test. A P value <0.05 was considered significant. 
RESULTS
Macrophage-Derived Hepcidin Directs Cardiac Remodeling After Myocardial Infarction
AMI promoted upregulation of Hamp mRNA and hepcidin protein levels in both infarcted heart and blood, as early as day 1 after the onset of ischemia ( Figure 1A ). Hepcidin was robustly expressed by cardiomyocytes ( Figure 1B ). We first hypothesized that cardiomyocytederived hepcidin was a regulator of cardiac function. We therefore developed mice with specific deletion of hepcidin in cardiomyocytes (αMHC Figure IA in the online-only Data Supplement), we were not able to uncover any effects on cardiac function and healing, suggesting that cardiomyocyte endogenously derived hepcidin was not involved in cardiac function in our experimental conditions ( Figure 1C and 1D ). Hepcidin is a master regulator of iron trafficking and systemic hepcidin deficiency correlated with massive iron accumulation. Nevertheless, serum and cardiac iron accumulation were similar in αMHC Myocardial infarction stimulates orchestrated waves of inflammation in the cardiac tissue, which by regulating local matrix deposition, vascular remodeling, infarct size, and cardiomyocyte survival/hypertrophy, mediate injury repair and determine heart function. 20 In particular, it is now well documented that injury signals can guide either direct recruitment of inflammatory cells to the infarcted tissue from BM-or spleen-derived circulating cells, or regulate their local activation and proliferation processes. We therefore considered that AMI stimulates the initiation of a series of hepcidin-dependent inflammatory responses with a major role in cardiac repair and function. Because the BM compartment is the major source of cardiac inflammatory cells in adult mice with AMI, we first assessed the role of BM-derived inflammatory cells expressing hepcidin. We generated WT and Hamp −/− chimeras lethally irradiated and transplanted with BM-derived cells from WT or hepcidindeficient animals (Hamp −/− ). After induction of AMI, we showed that cardiac function was elevated in WT mice transplanted with BM-derived Hamp −/− cells when compared with WT chimeras. Infarct size and collagen content were 1.7-and 1.5-fold lower, respectively, in WT mice transplanted with Hamp −/− BM compared with WT BM chimeric animals ( Figure 1E ). In addition, capillary density was higher in Hamp −/− BM chimeras ( Figure 1E ). In contrast, transplantation of BM WT cells in hepcidindeficient animals abolished the beneficial effects of hepcidin disruption on both cardiac function and remodeling ( Figure 1E ). Altogether, these results support a crucial role for hepcidin in BM-derived inflammatory cell-related effects in the infarcted heart.
The acute and sudden death of resident cells in the infarcted heart rapidly activates both innate and adaptive cell-mediated immune responses. Innate immune responses are powered by myeloid cells, which include monocytes, macrophages, mast cells, dendritic cells, and natural killer cells in addition to the neutrophilic, basophilic, and eosinophilic granulocytes. Furthermore, cell-mediated adaptive immunity driven via infiltration or polarization of T lymphocytes, and recruitment/maturation of B lymphocytes, also shape the dysfunctional infarcted heart. 16, [18] [19] [20] We first aimed to identify the type of inflammatory cells expressing hepcidin in the infarcted heart. Using fluorescence-activated cell-sorted cells, we showed that Hamp mRNA levels were mainly detected in (Figure 2A) . To assess the role of monocytes/macrophages expressing hepcidin, we then generated mice with specific deletion of hepcidin in myeloid cells (LysM 
Hepcidin-Deficient Macrophages Induce Cardiac Regeneration
We did not observe any significant changes in infarct size and apoptotic cell number at days 1, 3, and 7 after the onset of ischemia ( Figure IF in the online-only Data Supplement), suggesting that hepcidin deficiency in monocytes/macrophages did not confer any acute cardioprotective effects. Furthermore, the long-term pattern of cardiac recovery prompts us to speculate that part of the beneficial effect of hepcidin deficiency might rely on stimulation of endogenous cardiomyocyte renewal. Indeed, recent studies unravel that cardiomyocyte proliferation can occur during adult life, including in the human heart. 21, 22 Interestingly, recent works have also emphasized an unblemished influence of specific classes of monocytes/macrophages on bona fide cardiac regeneration. 17, 23 We first evidenced that ORIGINAL RESEARCH ARTICLE the number of cardiomyocytes was indeed increased in infarcted hearts of mice harboring monocyte/macrophage hepcidin deficiency ( Figure 3A) . Cardiomyocyte mitosis and cytokinesis were also assessed by colocalization of phosphohistone H3 (pH3) and Aurora B kinase, respectively, with cardiac troponin T. We found a significantly higher number of pH3-positive, and Aurora B kinase-positive, cardiomyocytes in infarcted hearts of LysM CRE/+ /Hamp f/f mice relative to their control littermates ( Figure 3A and Figure II in the online-only Data Supplement). Given the low rate of cardiomyocyte cell cycle completion in our experimental conditions, we used a distinctive model of cardiac regeneration in neonate animals where cardiac regeneration is followed after apical resection-induced heart injury. Indeed, neonatal mouse hearts display a transient regenerative potential and constitute a valuable model to decipher the interaction between inflammation and mammalian cardiac regeneration. 24 Hepcidin monocyte/macrophage deficiency accelerated cardiac regeneration as revealed by a reduction of infarct by scar size when compared with control littermates, at day 7 after apical resection ( Figure 3B and Figure III in the onlineonly Data Supplement). Conversely, capillary density was unaffected independent of the time point after apical resection ( Figure 3B ). The number of pH3-positive, and Aurora B kinase-positive, cardiomyocytes was also higher in resected hearts of LysM CRE/+ /Hamp f/f mice in reference to LysM CRE/+ /Hamp WT/f animals, at 7 days ( Figure 3C and Figure IV in the online-only Data Supplement). To establish whether the regenerated apex contains newly formed cardiomyocytes, we used 5-bromo-2-deoxyuridine in a pulse-chase experiment after apical resection. 5-Bromo-2-deoxyuridine-positive cardiomyocytes were identified within the newly formed apex at 7 days ( Figure 3C and Figure 
Macrophage-Derived Hepcidin Commands IL-4/IL-13-Dependent Cardiac Repair
We then analyzed the impact of hepcidin deficiency on the number and type of different subsets of monocytes and macrophages in the infarct milieu. In the mouse, circulating monocytes are phenotypically and functionally heterogeneous and can be separated according to Ly6C expression. 25 We showed that the number of car- (Figure 4A) . We also determined the macrophage content in our experimental conditions. Macrophages were first characterized as CD45 + /CD11b + /F4/80 + /CD64 + cells, and we revealed that hepcidin deficiency improved the number of cardiac macrophages, 3 and 7 days after the onset of ischemia ( Figure 4B ). The adult heart contains distinct resident macrophage subsets, with differing recruitment dynamics and ontogeny. 26 Figure 4B ). Conversely, the number of neutrophils as well as that of T and B lymphocytes were not affected by the lack of hepcidin (Figure V in the online-only Data Supplement).
Distinct inflammatory entities are known to trigger various macrophage profiles. 18 We then attempted to determine the main activator of hepcidin expression in macrophages. Macrophages were isolated from LysMCre + /Hamp WT/f or LysMCre + /Hamp f/f animals and stimulated with lipopolysaccharide (LPS) and recombinant IL-4 and IL-10, established factors that regulate macrophage phenotype. We revealed that Hamp mRNA levels were exclusively and markedly improved in LPS-treated macrophages ( Figure 5A ). We then speculated that hepcidin signaling might also modulate the macrophage activation state. As expected, macrophage activation was achieved in our in vitro conditions; ie, mRNAs of the M1 markers (Cox2, NOS2, CD86) were strongly expressed in WT macrophages treated with LPS, whereas the M2 marker mRNAs (CD206, RELMα, Arginase-1) were increased in WT macrophages treated with IL-4. Lower variations were observed among primary cultures for the expression of the M2 marker mRNAs in WT macrophages exposed to recombinant IL-10 (Figure 5B) . In LPS-treated hepcidin-deficient macrophages, the expression of CD206, M2 canonical marker, was elevated whereas the M1 marker, CD86, was reduced. However, the presence or absence of hepcidin did not modulate the expression of other M1 or M2 markers analyzed ( Figure 5B ). Alternatively, in the absence of hepcidin, we speculated that LPS stimulation could be ORIGINAL RESEARCH ARTICLE associated with modification of the repertoire of classic inflammatory mediators. LPS-treated hepcidin-deficient macrophages released IL-13 and to a lower extent IL-4, compared with LPS-treated WT macrophages (Figure 5C ). The concentration of IL-10 increased insufficiently to reach statistical significance. Conversely, IL-4, IL-5, IL-6, IL-12, CCL2, CCL7, interferon β, and tumor necrosis factor α levels were unaffected by the experimental conditions ( Figure VIA in the online-only Data Supplement).
Furthermore, we identified the inflammatory cytokines that could modulate the expression of hepcidin in situ within the ischemic heart. We showed that AMI promoted the upregulation of Hamp mRNA and hepcidin protein levels as early as day 1 after the onset of injury ( Figure 1A) . We therefore profiled the inflammatory cytokines that culminated in the infarcted heart 1 day after the ischemic insult. Protein levels of IL-6, IL-1βCCL2, and CCL7 were markedly elevated in the infarcted heart compared with sham-operated mice ( Figure 5D ) at day 1 after ischemia. Conversely, IL-5, IL-12, IL-18, and interferon γ levels were unaffected (Figure VIB in the online-only Data Supplement). We then tested the ability of IL-6, IL-1βCCL2, and CCL7 to upregulate Hamp mRNA levels in cultured macrophages. Only IL-6 was responsible for the induction of Hamp mRNA in our experimental conditions ( Figure 5E ). IL-6 treatment enhanced mRNA levels of CD206 and Arginase-1 M2 markers in hepcidin-deficient macrophages ( Figure 6A ). Stimulation of hepcidin-deficient macrophages with recombinant IL-6 induced the secretion of IL-13 and IL-4 compared with stimulated WT macrophages ( Figure 6B ). Because IL-6 is the prototypical activator of signal transducer and activator of transcription factor-3 (STAT3)-dependent cytokines, we assessed the prevalence of IL-6/STAT3 signaling in our experimental conditions. We first analyzed STAT3 activation in the infarcted heart. STAT3 phosphorylation was increased at day 1 and 3 after the onset of ischemia in LysM Figure 6C ). We then tested whether treatment of IL-6 could result in STAT3 phosphorylation. A peak of STAT3 phosphorylation was perceived at 12 h after the addition of IL-6. Interestingly, phospho-STAT3 was further increased in hepcidin-deficient macrophages treated with IL-6 ( Figure 6D ). Furthermore, STAT3 inhibition in IL-6-stimulated macrophages repressed IL-4 and IL-13 production, demonstrating that STAT3 phosphorylation is required in this process ( Figure 6E ). Altogether, our results suggest that in myocardial infarction, hepcidin induction by IL-6 acts as a brake to temper IL-4 and IL-13 secretion, rendering the heart refractory to repair. Importantly, the absence of hepcidin in macrophages lifts the brake and allows IL-6 to activate IL-4 and IL-13 secretion through phospho-STAT3, a prerequisite for cardiac improvement.
IL-4 and IL-13 are pleiotropic ILs produced especially by T-helper cells-type 2, but also by a wide variety of different cell types. As IL-4 and IL-13 are closely related genes, the IL-4 and IL-13 receptors share a common subunit (IL-4Rα) required for signal transduction. IL-4Rα paired with IL-13Rα1 can be activated by IL-13 or IL-4. Of note, genetic deficiency of IL-13 aggravates healing and remodeling after AMI. 27 IL-4 upregulation achieves a targeted increase in the number of M2-like macrophages and enhances the post-myocardial infarction prognosis.
28,29 IL-4 release from activated mononuclear leukocytes is also independently related to a reduced risk of cardiovascular disease. 30 Of great interest, IL-13Rα1, and to a lesser extent IL-4Rα, play a significant role in mediating cardiomyocyte cell cycle entry. 31 On the same note, systemic administration of IL-13 rescues defective heart regeneration in cardiomyocyte-specific Gata4 knockout neonate mice after cryoinjury. 32 IL-4 and IL-13 levels were improved in the cardiac tissue of LysM Figure 7B ). This effect was associated with an increase in infarct size and interstitial fibrosis, suggesting that IL-4/IL-13 release by cardiac hepcidin-deficient macrophage promote cardiac repair (Figure 7C and 7D) . Furthermore, we evidenced that the number of cardiomyocytes was reduced in infarcted heart of LysM 
DISCUSSION
In the present work, we unraveled a novel and unexpected role of the iron regulatory peptide, hepcidin, in controlling the ability of a specific subset of macrophages to modulate IL-4 and IL-13 secretion and subsequently impact cardiac repair after injury.
We evidenced for the first time that hepcidin dictates the reparative function of cardiac macrophages and locally controls cardiac repair. We showed that IL-6 induced Hamp mRNA in macrophages and IL-6 stimulation of macrophages lacking hepcidin fostered STAT3 phosphorylation, an instrumental step in the production of IL-4 and IL-13. Previous studies have suggested that IL-6 is necessary and sufficient to induce hepcidin during inflammation. 12 Our results are consistent with the described role of STAT3 in inducing the expression of IL-4 and IL-13 in T-helper cell-type 2 lymphocytes. 33 Interestingly, iron has been previously shown essential to activate CDK1, which in turn promotes the initiation and sustained signaling of the JAK1-STAT3 pathway. 34 Hence, one can speculate that in an infarcted heart, hepcidin induction by IL-6, or iron, could reduce the secretion of IL-4 and IL-13, thereby inhibiting cardiac repair. In contrast, hepcidin-deficiency in macrophages promoted the release of IL-4 and IL-13 by recombinant IL-6, opening the way for cardiac recovery. In this line, the failing hearts of patients with Friedreich ataxia are characterized by a substantial number of CD68-positive macrophages expressing hepcidin. 35 Our results also suggest that major endogenous repressors for cardiomyocyte proliferation are expressed in the cardiac tissue of neonate animals. In this line of reasoning, endogenous Hippo signaling has been shown to dampen cardiomyocyte renewal and tissue regeneration. 36 Therefore, the spatiotemporal modulation of inhibitory pathways in the nonpermissive cardiac milieu may restrain the cardiomyogenic capacity.
Heterogeneous populations of macrophage subtypes are seeded into cardiac tissue to perform key homeostatic repair functions but also undergird detrimental processes that contribute to adverse ventricular remodeling. 37 In particular, the plasticity of macrophages plays a decisive role in guiding their efficient phenotype to elicit polar opposite M1-like or M2-like activation mode associated with pro-or antireparative functions in cardiac homeostasis. 37 However, it is noteworthy that this classification as an M1 and M2 subpopulation is based on in vitro activation by T-helper cell-type 2 cytokines only illustrating 2 extreme activation modes. As a consequence, such nomenclature does not reflect the spectrum of functionally overlapping macrophage phenotypes in vivo within the cardiac milieu. 38 We clearly demonstrated that hepcidin-deficient macrophages in an M1-like polarization and inflammatory state displayed potent proreparative potential in cardiac milieu. Our findings support the concept that macrophages should be defined on the basis of their function and not solely on the descriptive catalogue of markers that is ascribed to the M1 and M2 nomenclature. 39 IL-4 and IL-13 are classical T-helper cell-type 2 immune cytokines. Both ILs have been shown to trigger M2-like activation of cultured macrophages. Nevertheless, our observation revealed autocrine production by macrophages. Although we detected modest concentrations of IL-4 and IL-13 secreted by macrophages, our observations are consistent with previous studies indicating that during the early phase after myocardial infarction, CD4 + T cells do not significantly contribute to IL-13 expression. 27 CD11b+/Ly6C Low monocytes/macro- ORIGINAL RESEARCH ARTICLE phages have been identified as the main IL-13 producers in a model of liver injury. 40 A potential homologous human cell population has also been recently described as IL-13-expressing CD14 dim CD16
+ monocytic cells in the peripheral blood of patients with heart failure. 41 In addition, macrophages undergoing efferocytosis have been shown to release IL-4. 42 Although we did not observe any significant modifications of M2 gene expression markers in our in vitro experimental conditions, one can still speculate that IL-4 and IL-13 secreted by cardiac macrophages might be an initial source of IL-4 and IL-13 to skew neighboring resident macrophages toward a reparative phenotype. This paracrine loop may promote clearance of damaged tissue and tissue repair before activation of IL-4 and IL-13 production by other cell types. 28 Besides their effect on macrophage profile, IL-4 and IL-13 can directly regulate cardiac remodeling. IL-13 has been long recognized as a potent fibrotic regulator. Its profibrotic activity involves both transforming growth factor-β-dependent 43, 44 and independent downstream signaling pathways. 45 Il-13 −/− mice challenged with AMI showed preferential mortality. Surviving Il-13 −/− animals displayed large infarct and dysfunctional infarct expansion in comparison with WT mice. 27 IL-4 treatment substantially strengthened the formation of connective tissues in the infarcted myocardium, improving postmyocardial infarction prognosis and cardiac structure and function. 28 We revealed that macrophage-derived IL-4/IL-13 regulate cardiac regeneration in both adult and neonatal mice. In adult mice, we detected a moderate increase in the number of cardiomyocytes with a weak reactivation of cardiomyocyte mitosis as previously reported in adult myocardium. 46 Only a small number of cardiomyocytes are responsible for the addition of the majority of new cardiomyocytes in response to injury. 47 Nevertheless, the adult myocardium undoubtedly displays a lower ability for cardiac repair. 48 We therefore assessed the impact of macrophage-producing IL-4/IL-13 in the early neonatal mouse heart that clearly regenerates after an injury. 24 In this experimental setting, we distinctly evidenced that IL-4/IL-13 released by cardiac macrophages accelerate cardiac regeneration. Mounting evidence suggests that cardiac macrophages control cardiac recovery. Hence, neonatal macrophageconditioned media are sufficient to promote neonatal rat cardiomyocyte proliferation in vitro. 26 Neonates depleted of macrophages are unable to regenerate myocardium and form fibrotic scars. 23 IL-4Rα and IL-13Rα1 are expressed in cultured neonatal cardiomyocytes, and IL-13 has been shown to directly stimulate cardiomyocyte cell cycle entry in vitro. 31 The myocardial scar was larger in cardiomyocyte-specific Gata4 knockout mice after cryo-injury, indicative of impaired regeneration. This defective regenerative process was associated with downregulation of IL-13 and was rescued by systemic administration of IL-13. 32 Similarly, IL-4 signaling is required for regeneration of skeletal muscle after injury. Muscle damage results in rapid recruitment of eosinophils, which secrete IL-4 to activate the regenerative actions of muscle resident progenitors. 49 Finally, smaller areas of injury that lack scarring appear to more effectively regenerate in animal models, and it is likely that the scar itself precludes effective regeneration from surrounding cardiomyocytes. One can then also speculate that IL-4/IL-13 downstream signaling might foster synergic effects on both cardiomyocyte renewal and scar formation. 48 In this line of reasoning, senescence-induced cellular response is characterized by abundant production of cytokines such as IL-6 that, together with the recruitment of inflammatory cells, results in tissue repair. 50 Therefore, our study supports the growing evidences that tissue damage-induced IL release can provoke cellular plasticity as well as adaptation of extracellular matrix microenvironment conducive to tissue repair.
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